Transthyretin Amyloidogenesis Inhibitors: From Discovery to Current Developments
- 10 December 2020
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 63 (23), 14228-14242
- https://doi.org/10.1021/acs.jmedchem.0c00934
Abstract
Transthyretin (TTR) is a homotetrameric protein in human plasma. The dissociation of the TTR tetramer and misfolding of the TTR monomer result in the formation of amyloid fibrils. Hereditary TTR amyloidosis is characterized by the extracellular deposition of amyloid fibrils containing TTR variants. The development of small molecules that kinetically stabilize the TTR tetramer is one of the effective strategies for the treatment of hereditary TTR amyloidosis. So far, several stabilizers have been discovered. Tafamidis is the only approved stabilizer for treatment of hereditary TTR amyloidosis, although two nucleic acid medicines that inhibit TTR synthesis, inotersen and patisiran, were recently approved for treatment of this disorder. In this Perspective, we seek to describe the representative kinetic stabilizers from discovery to development, interweaving the crystallographic study of the complex structures.Funding Information
- Takeda Science Foundation
- Japan Society for the Promotion of Science (16K08193, 19K07012)
This publication has 108 references indexed in Scilit:
- Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathyZeitschrift für Neurologie, 2013
- AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretinProceedings of the National Academy of Sciences of the United States of America, 2013
- Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosisAmyloid, 2013
- Stability of the Transthyretin Molecule as a Key Factor in the Interaction with A-Beta Peptide - Relevance in Alzheimer's DiseasePLOS ONE, 2012
- Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeProceedings of the National Academy of Sciences of the United States of America, 2012
- Finding a better path to drug selectivityDrug Discovery Today, 2011
- Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte ProteotoxicityScience Translational Medicine, 2011
- Trapping of palindromic ligands within native transthyretin prevents amyloid formationProceedings of the National Academy of Sciences of the United States of America, 2010
- Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse modelsJournal of Translational Medicine, 2010
- EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomersNature Structural & Molecular Biology, 2008